Aurealis Therapeutics Novel Chronic Wound Treatment to be Presented at the 4th Experts Meeting on Microbiome & Skin Health and Disease on December 15th, 2020

Basel Switzerland, Kuopio Finland – December 15th, 2020.

Haritha Samaranayake, MD, PhD, Medical Director of Aurealis Therapeutics will give a talk about development of AUP16, the company´s lead product for non-healing wounds such as diabetic foot ulcer. The presentation is titled “Development of a Live Biotherapeutic to treat diabetic foot ulcer“ and is scheduled for Tuesday, December 15th, 2020 at 14:30 CET.

More information about the event can be found here:

https://www.baseclear.com/experts-meetings/4th-microbiome-skin-health-and-disease/

For more information about Aurealis Therapeutics and AUP16, please contact:

Juha Yrjänheikki, CEO                                                                                                                              Email: juha(at)aurealistherapeutics.com

 

About Aurealis Therapeutics

Aurealis Therapeutics AG is a Swiss-Finnish private clinical stage biopharmaceutical company focusing on development of the clinical asset AUP-1602, the first-in-class four-in-one combination biologic drug for chronic wounds and other chronic inflammatory and regenerative diseases. The product is based on proprietary technology where genetically engineered lactic acid bacteria act as millions of small immune activating bioreactors in the human tissue and produce multiple human therapeutic proteins into target tissue to effectively and safely re-educate the distorted host immune microenvironment to proper state.

For more information:

Juha Yrjänheikki, CEO
Tel: +358 45 8433550
Email: juha(at)aurealistherapeutics.com